Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Kaufmann

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Response-guided neoadjuvant chemotherapy for breast cancerGunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro studyMichael Untch, Mahdi Rezai, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro studyGunter von Minckwitz, Mahdi Rezai, Sibylle Loibl, et al.
The Lancet. Oncology|December 14, 2012
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trialPaul E Goss, Ian E Smith, Joyce O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial dataSerban Dan Costa, Sibylle Loibl, Manfred Kaufmann, et al.
Breast Care (Basel, Switzerland)|November 5, 2010
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)Matthias W Beckmann, Jens-Uwe Blohmer, Serban-Dan Costa, et al.
Breast Cancer Research and Treatment|November 3, 2010
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trialsGunter von Minckwitz, Michael Untch, Eveline Nüesch, et al.
Lancet (London, England)|January 9, 2007
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Marion Procter, Richard D Gelber, et al.
The Lancet. Oncology|August 21, 2012
Treatment of breast cancer during pregnancy: an observational studySibylle Loibl, Sileny N Han, Gunter von Minckwitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factorsMartin Filipits, Margaretha Rudas, Raimund Jakesz, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Response-guided neoadjuvant chemotherapy for breast cancerGunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro studyMichael Untch, Mahdi Rezai, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro studyGunter von Minckwitz, Mahdi Rezai, Sibylle Loibl, et al.
The Lancet. Oncology|December 14, 2012
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trialPaul E Goss, Ian E Smith, Joyce O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial dataSerban Dan Costa, Sibylle Loibl, Manfred Kaufmann, et al.
Breast Care (Basel, Switzerland)|November 5, 2010
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)Matthias W Beckmann, Jens-Uwe Blohmer, Serban-Dan Costa, et al.
Breast Cancer Research and Treatment|November 3, 2010
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trialsGunter von Minckwitz, Michael Untch, Eveline Nüesch, et al.
Lancet (London, England)|January 9, 2007
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Marion Procter, Richard D Gelber, et al.
The Lancet. Oncology|August 21, 2012
Treatment of breast cancer during pregnancy: an observational studySibylle Loibl, Sileny N Han, Gunter von Minckwitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factorsMartin Filipits, Margaretha Rudas, Raimund Jakesz, et al.
Pageof 15